Effects of a dual CCR3 and H1-antagonist on symptoms and eosinophilic inflammation in allergic rhinitis

Respiratory Research

Volumn 11, Issue , 2010, Pages

  Greiff, Lennart ^a   Ahlström Emanuelsson, Cecilia ^a   Bahl, Ash ^b   Bengtsson, Thomas ^c   Dahlström, Kerstin ^c   Erjefält, Jonas ^d   Widegren, Henrik ^a   Andersson, Morgan ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c ASTRAZENECA R AND D   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ALPHA 2 MACROGLOBULIN; AZD 3778; CHEMOKINE RECEPTOR CCR3; EOSINOPHIL CATIONIC PROTEIN; HISTAMINE H1 RECEPTOR ANTAGONIST; LORATADINE; PLACEBO; TRYPTASE; UNCLASSIFIED DRUG; CCR3 PROTEIN, HUMAN;

ALLERGIC RHINITIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; EOSINOPHIL; FEMALE; HUMAN; LUNG LAVAGE; MALE; NASAL LAVAGE; PEAK NASAL INSPIRATORY FLOW; RANDOMIZED CONTROLLED TRIAL; ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG ANTAGONISM; HAY FEVER; LOEFFLER PNEUMONIA; MIDDLE AGED; PLACEBO EFFECT; TREATMENT OUTCOME;

ADULT; CROSS-OVER STUDIES; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PLACEBO EFFECT; PULMONARY EOSINOPHILIA; RECEPTORS, CCR3; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 77952528613     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-11-17     Document Type: Article

References (35)

1. Ponath PD, Qin S, Post TW, Wang J, Wu L, Gerard NP, Newman W, Gerard C, Mackay CR. Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med 1996, 183:2437-2448. 10.1084/jem.183.6.2437, 2192612, 8676064.
2. Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T-helper 2 cells. Science 1997, 227:2005-2007.
3. Uguccioni M, Mackay CR, Ochenberger B, Loetscher P, Rhis S, LaRosa GJ, Rao P, Ponath PD, Baggiolini M, Dahinden CA. High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines. J Clin Invest 1997, 100:1137-1143. 10.1172/JCI119624, 508288, 9276730.
4. Ochi H, Hirani WM, Yuan Q, Friend DS, Austen KF, Boyce JA. T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J Exp Med 1999, 190:267-280. 10.1084/jem.190.2.267, 2195573, 10432289.
5. Joubert P, Lajoie-Kadoch S, Labonte I, Gounni AS, Maghni K, Wellemans V, Chakir J, Laviolette M, Hamid Q, Lamkhioued B. CCR3 expression and function in asthmatic airway smooth muscle cells. J Immunol 2005, 175:2702-2708.
6. Beck LA, Tancowny B, Brummet ME, Asaki SY, Curry SL, Penno MB, Foster M, Bahl A, Stellato. Functional analysis of the chemokine receptor CCR3 on airway epithelial cells. J Immunol 2006, 177:3344-3354.
7. Fryer AD, Stein LH, Nie Z, Curtis DE, Evans CM, Hodgson ST, Jose PJ, Belmonte KE, Fitch E, Jacoby DB. Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction. J Clin Invest 2006, 116:228-236. 10.1172/JCI25423, 1319219, 16374515.
8. Elsner J, Escher SE, Forssmann U. Chemokine receptor antagonists: a novel therapeutic approach in allergic diseases. Allergy 2004, 59:1243-1258. 10.1111/j.1398-9995.2004.00710.x, 15507091.
9. Sabroe I, Conroy DM, Gerard NP, Li Y Collins PD, Post TW, Jose PJ, Williams TJ, Gerard CJ, Ponath PD. Cloning and characterization of the guinea pig eosinophil eotaxin receptor, C-C chemokine receptor-3: blockade using a monoclonal antibody in vivo. J Immunol 1998, 161:6139-6147.
10. Terada N, Hamano N, Kim WJ, Hirai K, Nakajima T, Yamada H, Kawasaki H, Yamashita T, Kishi H, Nomura T, Numata T, Yoshie O, Konno A. The kinetics of allergen-induced eotaxin level in nasal lavage fluid: its key role in eosinophil recruitment in nasal mucosa. Am J Respir Crit Care Med 2001, 164:575-579.
11. Ma W, Bryce PJ, Humbles AA, Laouini D, Yalcindag A, Alenius H, Friend DS, Oettgen HC, Gerard C, Geha RS. CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation. J Clin Invest 2002, 109:621-628. 150891, 11877470.
12. Humbles AA, Lu B, Friend DS, Okinaga S, Lora J, Al-Garawi A, Martin TR, Gerard NP, Gerard C. The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness. Proc Natl Acad Sci USA 2002, 99:1479-1484. 10.1073/pnas.261462598, 122216, 11830666.
13. Rajalulasingam K, Hamis Q, O'Brien F, Shotman E, Jose PJ, Williams TJ, Jacobson M, Barkans J, Durham SR. RANTES in human allergen-induced rhinitis: cellular source and relation to tissue eosinophilia. Am J Respir Crit Care Med 1997, 155:696-703.
14. Ying S, Meng Q, Zeibecoglou K, Robinson DS, Macfarlane A, Humbert M, Kay AB. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and non-atopic (intrinsic) asthmatics. J Immunol 1999, 163:6321-6329.
15. Greiff L, Petersen H, Mattsson E, Andersson M, Erjefält JS, Linden M, Svensson C, Persson CG. Mucosal output of eotaxin in allergic rhinitis and its attenuation by topical glucocorticosteroid treatment. Clin Exp Allergy 2001, 31:1321-1327. 10.1046/j.1365-2222.2001.01029.x, 11529904.
16. Lilly CM, Nakamura H, Belostotsky OI, Haley KJ, Garcia-Zepeda EA, Luster AD, Israel E. Eotaxin expression after segmental allergen challenge in subjects with atopic asthma. Am J Respir Crit Care Med 2001, 163:1669-1675.
17. Gauvreau GM, Boulet LP, Cockcroft DW, Baatjes A, Cote J, Deschesnes F, Davis B, Strinich T, Howie K, Duong M, Watson RM, Renzi PM, O'Byrne PM. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med 2008, 177:952-958. 10.1164/rccm.200708-1251OC, 18244953.
18. Wegmann M, Goggel R, Sel S, Sel S, Erb KJ, Kalkbrenner F, Renz H, Garn H. Effects of a low molecular weight CCR-3 antagonist on chronic experimental asthma. Am J Respir Cell Mol Biol 2007, 36:61-67. 10.1165/rcmb.2006-0188OC, 16917075.
19. Das AM, Vaddi KG, Solomon KA, Krauthauser C, Jiang X, McIntyre KW, Yang XX, Wadman E, Welch P, Covington M, Graden D, Yeleswaram K, Trzaskos JM, Newton RC, Mandlekar S, Ko SS, Carter PH, Davies P. Selective inhibition of eosinophil influx into the lung by small molecule CC chemokine receptor 3 antagonists in mouse models of allergic inflammation. J Pharmacol Exp Ther 2006, 318:411-417. 10.1124/jpet.105.099812, 16614169.
20. Nakamura T, Ohbayashi M, Toda M, Hall DA, Horgan CM, Ono SJ. A specific CCR3 chemokine receptor antagonist inhibits both early and late phase allergic inflammation in the conjunctiva. Immunol Res 2005, 33:213-221. 10.1385/IR:33:3:213, 16461999.
21. Suzuki K, Morakata T, Morihira K, Sato I, Takizawa S, Kaneko M, Takahashi K, Shimizu Y. In vitro and in vivo characterization of a novel CCR3 antagonist, YM-344031. Biochem Biophys Res Commun 2006, 339:1217-1223. 10.1016/j.bbrc.2005.11.141, 16343433.
22. Morakata T, Suzuki K, Masunaga Y, Tagushi K, Morihira K, Sato I, Fujii M, Takizawa S, Torii Y, Yamamoto N, Kaneko M, Yamada T, Takahashi K, Shimizu Y. A novel, selective, and orally available antagonist for CC chemokine receptor 3. J Pharmacol Exp Ther 2006, 317:244-250. 10.1124/jpet.105.097048, 16339911.
23. DeLucca GV, Kim UT, Vargo BJ, Duncia JV, Santella JB, Gardner DS, Zheng C, Liauw A, Wang Z, Emmett G, Wacker DA, Welsh PK, Covington M, Stowell NC, Wadman EA, Das AM, Davies P, Yeleswaram S, Graden GM, Solomon KA, Newton RC, Trainor GL, Decicco CP, Ko SS. Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency. J Med Chem 2005, 48:2194-2211. 10.1021/jm049530m, 15771462.
24. Ahlström-Emanuelsson V, Persson CG, Svensson C, Andersson M, Hosszu Z, Åkerlund A, Greiff L. Establishing a model of seasonal allergic rhinitis and demonstrating dose-response to a topical glucocorticosteroid. Ann Allergy Asthma Immunol 2002, 89:159-165.
25. Ahlström-Emanuelsson C, Andersson A, Persson CG, Thorsson L, Greiff L. Effects of topical formoterol alone and in combination with budesonide in a pollen season model of allergic rhinitis. Respir Med 2007, 101:1106-1112. 10.1016/j.rmed.2006.11.017, 17215115.
26. Persson CG, Erjefält JS, Greiff L, Andersson M, Erjefält I, Godfrey RW, Korsgren M, Linden M, Sundler F, Svensson C. Plasma-derived proteins in airway defence, disease and repair of epithelial injury. Eur Respir J 1998, 11:958-970. 10.1183/09031936.98.11040958, 9623704.
27. Greiff L, Andersson M, Persson CGA. Nasal secretions/exudations: Collection and approaches to analysis. Methods in molecular medicine: Human airway inflammation 2001, 56:61-73. Totowa (NJ): Humana Press, Rogers D, Donnelly L.
28. Korsgren M, Andersson M, Borgå O, Larsson L, Aldén-Raboisson M, Malmqvist U, Greiff L. Clinical efficacy and pharmacokinetic profile of intranasal and oral cetirizine in a pollen season model of allergic rhinitis. Ann Allergy Asthma Immunol 2007, 98:316-321.
29. Erjefält JS, Greiff L, Andersson M, Ädelroth E, Jeffery PK, Persson CGA. Degranulation patterns of eosinophil granulocytes as determinants of eosinophil driven disease. Thorax 2001, 51:159-163.
30. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, Hansel TT, Holgate ST, Sterk PJ, Barnes PJ. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356:2144-2148. 10.1016/S0140-6736(00)03496-6, 11191542.
31. Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS, Danzig M, Cuss F, Pauwels RA. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003, 167:1655-1659. 10.1164/rccm.200206-525OC, 12649124.
32. Menzies-Gow A, Flood-Page P, Sehmi R, Burman J, Hamid Q, Robinson DS, Kay AB, Denburg J. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 2003, 111:714-719. 10.1067/mai.2003.1382, 12704348.
33. Johnston SL, Pattemore PK, Sanderson G, Smith S, Campbell MJ, Josephs LK, Cunningham A, Robinson BS, Myint SH, Ward ME, Tyrell DA, Holgate ST. The relationship between upper respiratory tract infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med 1996, 154:654-660.
34. Greiff L, Andersson M, Andersson E, Linden M, Myint S, Svensson C, Persson CG. Experimental common colds increases mucosal output of eotaxin in atopic individuals. Allergy 1999, 54:1204-1208. 10.1034/j.1398-9995.1999.00172.x, 10604558.
35. Teran LM, Seminario MC, Shute JK, Papi A, Compton SJ, Low JL, Gleich GJ, Johnston SL. RANTES, macrophage-inhibitory protein 1 alpha, and the eosinophil product major basic protein are released into upper respiratory secretions during virus-induced asthma exacerbations in children. J Infect Dis 1999, 179:677-681. 10.1086/314618, 9952375.